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Background: Phosphate binders’ constituents have alkalotic or acidotic properties and may contribute to acid base
balance in haemodialysis patients. This study aimed to investigate the differential effects of phosphate binders on
pre-dialysis serum bicarbonate in End Stage Kidney Disease patients on maintenance haemodialysis.
Methods: Stable out-patients having satellite haemodialysis for at least 3 months were retrospectively studied for
18 months, excluding those with other medical causes for metabolic acidosis. Blood results were censored for
inpatient episodes, at the time of death, renal transplant or dialysis modality change. Multivariable multilevel mixed-
effects linear regression was used and five groups of phosphate binders were compared: Group A(Calcium (Ca)
and/or Aluminium (Al) binders); B(Sevelamer hydrochloride (SH) alone); C(lanthanum carbonate (LC) alone); D(SH
and Ca/Al), E(LC and Ca/Al).
Results: Of 320 patients, 292 were eligible for analysis with a mean follow-up of 15.54 (standard deviation, SD 3.98)
months. Similar mean pre-dialysis serum levels of bicarbonate were observed at all 6 month-interval analyses. At
18th months, observed mean serum bicarbonate levels in mmol/L were Group B: 21.58 (SD 2.82, P<0.001), C: 23.29
(SD 2.80, P=0.02), D: 21.56 (SD 3.00, P<0.001), and E: 21.29 (SD 3.62, P=0.92) compared with Group A: 22.98 (SD 2.77).
Mean serum bicarbonate was related to total SH dose in mmol/L: 22.34 (SD 2.56) for SH <2.5 g/day, 21.61 (SD 2.62)
for SH 2.5-4.8 g/day, 21.04 (SD 3.31) for SH >4.8 g/day compared with 22.85 (SD 2.91) for non-users; P-trend<0.001.
Conclusions: Phosphate binders’ constituents may contribute to/protect against a predisposition to pre-dialysis
metabolic acidosis. This may be dose dependant in patients taking Sevelamer Hydrochloride.
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An increased anion gap metabolic acidosis is a character-
istic of End Stage Kidney Disease (ESKD). Recognition of
the metabolic acidosis in haemodialysis is essential be-
cause of the serious complications that can arise. The clin-
ical importance of this is summarized in Table 1 [1,2].
According to the Caring for Australians with Renal Im-
pairment (CARI) Guidelines in 2000, pre-dialysis serum
bicarbonate in haemodialysis patient should be in the
range of 23–24 mmol/L [3]. Contrary to available
evidence; a few epidemiologic studies showed that a mild
degree of metabolic acidosis was not associated with* Correspondence: zaw.thet@hotmail.com
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reproduction in any medium, provided the orincreased risk of morbidity and mortality [4,5]. In 2009,
the British Renal Association recommended that pre-
dialysis serum bicarbonate concentrations, measured with
minimum delay after venepuncture, should be between 18
and 24 mmol/L [6].
Hyperphosphataemia, a frequent and serious complica-
tion of ESKD, partially contributes to metabolic acidosis
which can be temporarily corrected by haemodialysis.
Phosphate binders presently available in Australia include
aluminium (Al) binders, calcium (Ca) binders and non-
calcium and non-aluminium binders such as sevelamer
hydrochloride (SH) and lanthanum carbonate (LC). Phos-
phate binders’ constituents have alkalotic or acidotic
properties and may contribute to acid base balance in
haemodialysis patients. Hyperphosphatemia itself andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Potential adverse effects of metabolic acidosis in patients with chronic kidney disease
Effect Comment
Muscle wasting Seen with even mild metabolic acidosis (important factor in causing muscle wasting in patients with CKD)
Reduced albumin synthesis Acidosis is one of many factors contributing to hypoalbuminemia in patients with CKD
Bone disease Acidosis contributes to the genesis of bone disease by diverse mechanisms; contributory rather than primary
mechanism in producing bone disease
Direct effects
• Physicochemical dissolution of bone• Decreased function of osteoblast
• Increased function of osteoclast
Indirect effects
• Increased release of parathyroid hormone
• Increased number of parathyroid hormone receptors
• Increased binding of parathyroid hormone to its receptor
• Decreased activity of 1-a hydroxylase
Impaired insulin sensitivity Effect unclear given the impact of changes in insulin metabolism with renal failure; could induce metabolic
changes similar to those seen in syndrome X*
B2-Microglobulin accumulation Found with studies of acetate v bicarbonate dialysis in dialysis patients; no studies of patients with CKD not
on dialysis therapy
Exacerbation of renal failure Data for and against role of acidosis in progression of renal failure
Impaired thyroid metabolism May contribute to abnormalities in basal metabolic rate
Stunted growth in children Reversed in part by correction of acidosis
Cardiac disease Role in the development of cardiac disease is theoretical, not proven
Increased inflammation Conflicting evidence for and against the role of acidosis in dialysis patients
Syndrome X* is characterized by dislipidemia, hyperinsulinemia, hypertension, abdominal obesity, glucose intolerance and renal resistance.
From Kraut JA et al. [1]: Metabolic Acidosis of CKD: Diagnosis, Clinical Characteristics and Treatment. AJKD 2005;45(6):978–93.
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the patients. This study aimed to investigate the differential
effects of phosphate binders on pre-dialysis serum bicar-
bonate in ESKD patients on maintenance haemodialysis
when comparing patients taking different binders.
Aluminium (Al) binders contain an alkali that might
partially compensate metabolic acidosis in ESKD patients.
Aluminium phosphate binders are generally avoided be-
cause of concerns of end-organ damage. As a result, alu-
minium binders have largely been replaced by the calcium
based binders. Calcium carbonate as a phosphate binder
delivers an alkali and may raise serum bicarbonate. Simi-
larly the acetate in calcium acetate when used as a phos-
phate binder is metabolized to bicarbonate in the liver.
The efficacy of calcium phosphate binders is offset by the
potential side effects associated with increased calcium ab-
sorption. Sevelamer hydrochloride is a non-aluminum and
non-calcium phosphate binder which has proven to be ef-
fective in lowering phosphate without raising calcium
levels and causing harmful effects on renal bone disease
[7,8]. SH acts like an ion-exchange resin that releases
chloride in exchange of phosphate ions. The chloride thus
released is buffered by bicarbonate, contributing to meta-
bolic acidosis [9-14]. Lanthanum carbonate is a non- alu-
minium, non-calcium, phosphate binder that is effective
and well tolerated. Lanthanum carbonate contains analkali and it is expected to raise bicarbonate and act as a
buffer. However, there is a concern regarding potential
lanthanum accumulation in the tissues over time and pos-
sible long term side-effects. Despite concerns about long-
term effects of lanthanum, long term follow up for 6 years
has not supported these concerns [15].
Adequate, safe control of phosphate and calcium levels
with phosphate binders is therefore difficult and multiple
agents may be required. In Australia, first line treatment
for hyerphosphataemia remains calcium based phos-
phate binders in patients with low risk for vascular calci-
fication because of Pharmaceutical Benefit Scheme (PBS)
restrictions on using non-calcium and non-aluminum
binders in CKD and denovo in haemodilysis. Second line
treatment such as SH or LC is indicated with or without
combination of first line binders only in patients with high
risk of vascular calcification and/or hyperphosphatemia
that is not controlled by first line phosphate binders.
There is a tendency in practice to combine phosphate
binders in an attempt to improve efficacy or to minimize
side effects of binders. Although there are cross-over or
head to head studies comparing efficacy of phosphate
binders and suggesting increased risk of metabolic acid-
osis in patients treated with SH, there is no study to in-
vestigate long term individual and combined effects of
phosphate binders on acid base balance in haemodialysis
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This retrospective study included 292 stable Melbourne
Health and Western Health out-patients who received sat-
ellite haemodialysis for a period of at least three months.
Both Western & Melbourne Health units practiced the
same audit policy in order to achieve CARI Guidelines’
target of pre-dialysis bicarbonate of 23–24 mmol/L. It was
a standard practice to supplement alkai by increasing
dialysate bicarbonate concentration to 40 mmol/L from
35 mmol/L at monthly blood audit in both units when
serum bicarbonate fell below 18 mmol/L. In order to
avoid post-dialysis alkalemia, dialysate bicarbonate con-
centrations were modified back to 35 mmol/L when
pre-dialysis serum bicarbonate was ≥24 mmol/L. The
monthly blood tests were audited by these rules in both
centres by a single Nephrologist in the respective
centres.
This study was approved by Melbourne Health and
Western Health Ethics committees. Patients with other
medical causes for metabolic acidosis were excluded. Exclu-
sion criteria were alcohol abuse, recurrent hypoglycemia,
decompensated organ failure, cancer with active treatment
or life expectancy less than a year, recurrent diabetic
ketoacidosis, severe gastromotility disorders, pancreatic or
biliary fistula, uretosigmoidostomy, long term nephrostomy
tube and renal tubular acidosis. These audited patients were
stable out-patients having dietary advice routinely in out-
patient clinics and dialysis three times per week. Monthly
patient information was recorded from December 2008 to
June 2010. All blood samples were analyzed without delay
by Melbourne Health Pathology by standard laboratory
methods. Blood results were censored for inpatient epi-
sodes, at the time of death, renal transplant or dialysis mo-
dality change.
Statistical analysis
Long term individual and combined effects of phos-
phate binders on pre-dialysis serum bicarbonate, phos-
phate, potassium and corrected calcium were compared
for five groups: Group A (Calcium (Ca) and/or Alumin-
ium (Al) binders); B (Sevelamer hydrochloride (SH)
alone); C (lanthanum carbonate (LC) alone); D (SH and
Ca/Al), E (LC and Ca/Al). Pre-dialysis serum bicarbon-
ate, phosphate, potassium and corrected calcium were
also compared for three dosing groups of SH: low dose
(SH <2.5 g/day), medium dose (SH 2.5-4.8 g/day) and
high dose (SH >4.8 g/day). Allowing both random and
fixed effects of medication along the study period,
multilevel mixed-effects linear regression was used toestimate mean differences and 95% confidence intervals
(CIs) at three different time points by six months inter-
vals (June 2009, December 2009 and June 2010) after
adjusting for sex, age and diabetes. All reported statis-
tical tests were two-sided and P<0.05 was considered
statistically significant. All statistical analyses were done
using Stata 11.0 [16].
Results
Of 320 patients, 292 (63% male) were eligible for ana-
lysis with a mean follow-up of 15.54 (standard devi-
ation, SD 3.98) months. Baseline characteristics of
these patients are shown in Table 2. The majority of pa-
tients was Caucasian (55%) and had been on dialysis
for, on average, 2 years (mean 49.22 months; SD 39.65).
Mean urea reduction ratio (URR) was 72.76% (SD 6.96).
Diabetes mellitus (40%) was the most common aeti-
ology of ESKD in this study.
Table 3 shows phosphate binder usage at different time
points of 6 month-interval analysis: Group A (Ca/Al) ap-
proximately 34%-37%, Group B (SH) 27%-29%, Group C
(LC) 8%-9%, Group D (SH plus Ca/Al) 21%-23% and
Group E (LC plus Ca/Al) 7%-8%. Because of Australian
PBS restrictions at the time, the number of patients using
lanthanum carbonate was small. Therefore, results of
group C (LC) and group E (LC plus Ca/AL) should be
interpreted with caution. Majority (approximately 90-95%)
remained on the same binders at each of the 6 month
study period. Both Melbourne and Western Health units
phased out an oral bicarbonate supplementation method.
During our study period, auditors identified only 2% of
the cohort who remained on oral sodium bicarbonate and
terminated the treatment completely. Patients who re-
quired an increased dose of dialysate bicarbonate were
summarized in Table 4. Overall, compared to Group (A)
Ca/Al, Group B (SH) and Group D (SH plus Ca/Al) re-
ceived more alkali supplementation by increasing dose of
dialysate bicarbonate.
Pre-dialysis observed mean levels and estimated mean
differences of serum bicarbonate, phosphate, potassium,
and corrected calcium for all five phosphate binder
groups were shown in Table 5. Figure 1 reveals the time
course changes in pre-dialysis parameters: observed
mean levels of serum bicarbonate, phosphate, potassium
and corrected calcium. When mean serum bicarbonate
levels were compared with Group A (Ca/Al), serum bi-
carbonate levels were significantly lower in group B (SH)
and group D (SH plus Ca/Al) (P<0.001) at all points of
6 month interval analysis. Pre-dialysis serum potassium
was marginally elevated in Group B (SH) and Group D (SH
plus Ca/Al) (P<0.001) compared with Group A (Ca/Al).
In sub-group analysis, patients taking SH (alone or
with other binders) were compared in three dosing
groups (Table 6 and Figure 2). A significant correlation
Table 2 Baseline characteristics of patients in this study
Total no (%)
(n=292)
Group A (n=108) Group B (n=80) Group C (n=24) Group D (n=60) Group E (n=20)
Sex
Male 184 (63) 65 49 14 41 15
Female 108 (37) 43 31 10 19 5
Race
Caucasian 162 (55) 57 48 20 30 7
Asian 38 (13) 15 9 0 14 0
African 6 (2) 2 1 0 2 1
Australian Aborigines 1 (0.5) 1 0 0 0 0
Pacific Islander 7 (2.5) 4 2 0 1 0
Middle Eastern 14 (5) 6 4 0 2 2
Other 11 (4) 5 2 0 4 0
Unknown 53 (18) 18 14 4 7 10
Aetiology
Polycystic kidney disease 12 (4) 1 5 1 3 2
Diabetes type II 70 (24) 23 23 3 18 3
Diabetes type I 46 (16) 21 5 5 10 5
Focal Segmental Glomerular Sclerosis 31 (11) 12 4 4 7 4
Glomerular Nephritis 21 (7) 5 7 4 4 1
Hypertension 4 (1) 1 1 1 1 0
Idiopathic 2 (1) 1 0 0 1 0
Ig A disease 24 (8) 10 5 1 6 2
Reflux nephropathy 14 (5) 6 5 1 2 0
Other 17 (6) 7 8 1 1 0
Renal Calculus 2 (1) 1 1 0 0 0
Renovascular disease 10 (3) 4 4 1 1 0
Unknown 39 (13) 16 12 2 6 3
Diabetes
Yes 138 (47) 51 37 11 29 10
No 154 (53) 57 43 13 31 10
Ischaemic heart disease
Yes 117 (40) 50 24 7 26 10
No 148 (51) 48 48 15 30 7
Unknown 27 (9) 10 8 2 4 3
Parathyroidectomy
Yes 17 (6) 6 2 1 7 1
No 275 (94) 102 78 23 53 19
Mean (SD)
Age (year) 65.56 (14.40) 67.51 (13.90) 66.33 (14.82) 66.29 (16.31) 62.06 (13.39) 61.83 (15.50)
Haemodialysis period (month) 49.22 (39.65) 46.52 (40.58) 47.86 (39.74) 75.25 (40.79) 49.06 (35.56) 38.10 (15.56)
Urea Reduction Ratio 72.76 (6.96) 71.76 (8.08) 73.93 (6.20) 75.30 (6.51) 71.99 (6.07) 73.30 (5.21)
Follow-up duration (month) 15.54 (3.98) 15.22 (4.22) 16.12 (3.15) 16.02 (3.29) 16.39 (3.37) 15.47 (4.14)
SD=standard deviation.
Group A (Calcium and/or Aluminum binders).
Group B (Sevelamer hydrochloride alone).
Group C (Lanthanum carbonate alone).
Group D (Sevelamer hydrochloride and Calcium and/or Aluminum binders).
Group E (Lanthanum carbonate and Calcium and/or Aluminum binders).
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Table 3 Number of patients (%) at each category of
phosphate binders usage at 6 month interval of analysis






Group A (Ca & Al) 108 (37) 83 (32) 81 (34)
Group B (SH) 80 (27) 76 (29) 68 (29)
Group C (LC) 24 (8) 22 (8) 21 (9)
Group D (SH & Ca/Al) 60 (21) 59 (23) 50 (21)
Group E (LC & Ca/Al) 20 (7) 20 (8) 17 (7)
Group A (Calcium and/or Aluminum binders).
Group B (Sevelamer hydrochloride alone).
Group C (Lanthanum carbonate alone).
Group D (Sevelamer hydrochloride and Calcium and/or Aluminum binders).
Group E (Lanthanum carbonate and Calcium and/or Aluminum binders).
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bonate, potassium and corrected calcium levels was ob-
served over the whole study period. The higher the
dose of SH given in ESKD patients on maintenance
haemodialysis, the lower the mean serum bicarbonate
level and the higher the mean serum potassium level
(P-trend <0.001). There were no major difference in
mean serum pre-dialysis phosphate at the end of study
(P-trend =0.53). Mean serum corrected calcium (p <0.001)
was marginally decreased in patients treated with SH (SH
alone and/or conventional binders) when compared to
non-SH users at all points of 6 month-interval sub-group
analysis.
Discussion
In our study, the control of serum phosphate by SH in
ESKD patients might occur at the expense of lowering
serum bicarbonate. The higher the dose of SH given in
ESKD patients, the lower the mean serum bicarbonate
level. Hyperkalemia may be explained by aggravation of
metabolic acid by SH. Oka et al., reported that the levels
of pre-dialysis serum bicarbonate significantly andTable 4 Number of patients (%) who required increased














Group A (Ca & Al) 10/108 5/83 6/81
Group B (SH) 21/80 17/76 6/68
Group C (LC) 0/24 0/22 1/21
Group D (SH & Ca/Al) 19/60 13/59 5/50
Group E (LC & Ca/Al) 1/20 2/20 3/17
P Value (B&D cf. A) <0.001 <0.004 0.67
Group A (Calcium and/or Aluminum binders).
Group B (Sevelamer hydrochloride alone).
Group C (Lanthanum carbonate alone).
Group D (Sevelamer hydrochloride and Calcium and/or Aluminum binders).
Group E (Lanthanum carbonate and Calcium and/or Aluminum binders).negatively correlated with the daily SH dosage [12]. Meta-
bolic acidosis in hemodialysis patients may be associated
with other causes related to dialysis and its prescription.
In our study, mean URR suggested that patients were ad-
equately dialyzed with no difference between the study
groups. In our study, other important dialysis/patients re-
lated factors: for example- interdialytic fluid gain, adminis-
tration of alkali, excessive protein intake, hypotension
during dialysis and chronic hyperparathyroidism were not
taken into account in interpretation of metabolic acidosis.
In 2009, the British Renal Association (BRA) guidelines
recommended lower level of pre-dialysis serum bicarbon-
ate levels than the targets of earlier local (CARI, 2000) and
international (The National Kidney Foundation Disease
Outcomes Quality Initiative KDOQI, 2003) guidelines
based on the evidence of epidemiologic studies [3,6,17].
As epidemiologic analysis can identify only an association
of metabolic acidosis and patients’ mortality/morbidity,
causal relationships need to be demonstrated by clinical
trials. Hence, the results of epidemiologic data analysis
should be interpreted with caution.
SH, LC and Ca/Al phosphate binders are very effective
in controlling serum phosphate and calcium levels [7,8].
The recommended Caring for Australians with Renal
Impairment (CARI) targets for pre-dialysis serum phos-
phate and corrected calcium were 2.1-2.4 mmol/L and
0.8-1.6 mmol/L respectively. Mean pre-dialysis serum
corrected calcium levels were within the CARI targets.
In our study, mean serum corrected calcium (P<0.001)
was marginally decreased in patients treated with SH
when compared to conventional binder users. A study of
ten-year experience with sevelamer and calcium binders
suggested that sevelamer might improve vascular and bone
health and perhaps, mortality in haemodialysis patients [8].
Our serum phosphate levels were above the targets in all
five groups of patients. A number of other factors which
were not reviewed in this study may have contributed to
the poor achievement of serum phosphate target levels, in-
cluding poor patient insight into the consequences of
hyperphosphatemia, variable dietary management, and
poor adherence with binders, Hyperphosphataemia itself
partially contributes to metabolic acidosis. As mean phos-
phate levels did not differ significantly between the groups
at the end of our study, differences in mean serum bicar-
bonate among the groups could not be explained by
hyperphosphatemia.
Several investigators have studied metabolic acidosis
treatment in ESKD patients on maintenance haemodi-
alysis. Alkali has usually been provided either by increas-
ing dialysate bicarbonate concentration, oral bicarbonate
administration, or a combination of both [18-24]. Oral
administration of sodium bicarbonate may result in vol-
ume overload and possibly diminish the effectiveness of
sevelamer, as the alkali may compete with phosphate for
Table 5 Pre-dialysis mean serum level of bicarbonate, phosphate, potassium and corrected calcium for different combinations of phosphate binders
June 2009 December 2009 June 2010
Mean (SD)# Mean difference (95% CI)* P Mean (SD)# Mean difference (95% CI)* P Mean (SD)# Mean difference (95% CI)* P
Bicarbonate
Group A (Ca & Al) 22.94 (2.83) ref 22.89 (2.76) ref 22.98 (2.77) ref
Group B (SH) 21.26 (2.72) −1.56 (−2.09 to −1.02) <0.001 21.25 (2.83) −1.18 (−1.59 to −0.78) <0.001 21.58 (2.82) −0.95 (−1.29 to −0.60) <0.001
Group C (LC) 22.83 (1.17) −0.01 (−2.76 to 2.74) 0.98 23.76 (2.57) 0.74 (0.05 to 1.43) 0.04 23.29 (2.80) 0.58 (0.10 to 1.05) 0.02
Group D (SH & Ca/Al) 21.17 (3.00) −1.30 (−1.83 to −0.77) <0.001 21.31 (3.00) −0.69 (−1.10 to −0.29) <0.001 21.56 (3.00) −0.64 (−1.00 to −0.28) <0.001
Group E (LC & Ca/Al) 19.50 (4.45) −1.40 (−2.79 to 0.00) 0.05 20.59 (3.59) −0.44 (−1.09 to 0.22) 0.19 21.29 (3.62) −0.03 (−0.54 to 0.49) 0.92
Phosphate^
Group A (Ca & Al) 1.53 (0.51) ref 1.52 (0.50) ref 1.50 (0.49) ref
Group B (SH) 1.48 (0.41) −0.01 (−0.10 to 0.08) 0.83 1.52 (0.44) 0.03 (−0.04 to 0.10) 0.35 1.52 (0.45) −0.01 (−0.07 to 0.05) 0.70
Group C (LC) 1.73 (0.63) 0.32 (−0.12 to 0.77) 0.16 1.67 (0.54) 0.08 (−0.04 to 0.19) 0.18 1.67 (0.53) 0.04 (−0.03 to 0.12) 0.27
Group D (SH & Ca/Al) 1.73 (0.57) 0.08 (−0.02 to 0.17) 0.11 1.70 (0.54) 0.02 (−0.05 to 0.09) 0.65 1.68 (0.55) 0.00 (−0.06 to 0.06) 0.97
Group E (LC & Ca/Al) 2.12 (0.58) 0.29 (0.05 to 0.52) 0.02 2.09 (0.74) 0.16 (0.06 to 0.27) 0.003 2.01 (0.77) 0.06 (−0.02 to 0.15) 0.14
Potassium
Group A (Ca & Al) 4.84 (0.70) ref 4.82 (0.69) ref 4.83 (0.70) ref
Group B (SH) 5.04 (0.71) 0.14 (0.01 to 0.27) 0.04 5.03 (0.72) 0.17 (0.07 to 0.27) <0.001 5.05 (0.70) 0.16 (0.08 to 0.24) <0.001
Group C (LC) 4.87 (0.36) 0.21 (−0.45 to 0.87) 0.54 4.76 (0.74) −0.02 (−0.18 to 0.14) 0.84 4.84 (0.81) 0.05 (−0.06 to 0.16) 0.38
Group D (SH & Ca/Al) 5.18 (0.72) 0.20 (0.06 to 0.33) <0.001 5.13 (0.69) 0.14 (0.04 to 0.23) 0.01 5.12 (0.68) 0.15 (0.06 to 0.23) <0.001
Group E (LC & Ca/Al) 5.09 (0.62) 0.18 (−0.16 to 0.51) 0.30 5.01 (0.79) −0.04 (−0.19 to 0.12) 0.63 5.08 (0.77) 0.03 (−0.10 to 0.15) 0.68
Corrected Calcium^
Group A (Ca & Al) 2.35 (0.19) ref 2.35 (0.18) ref 2.37 (0.18) ref
Group B (SH) 2.33 (0.19) −0.03 (−0.06 to 0.01) 0.14 2.33 (0.19) −0.03 (−0.06 to −0.01) 0.01 2.34 (0.19) −0.04 (−0.06 to −0.02) <0.001
Group C (LC) 2.18 (0.15) −0.12 (−0.30 to 0.05) 1.17 2.36 (0.18) −0.01 (−0.05 to 0.03) 0.73 2.39 (0.18) 0.01 (−0.02 to 0.04) 0.60
Group D (SH & Ca/Al) 2.30 (0.20) −0.05 (−0.09 to −0.02) 0.004 2.31 (0.19) −0.04 (−0.06 to −0.01) 0.003 2.32 (0.19) −0.04 (−0.06 to −0.02) <0.001
Group E (LC & Ca/Al) 2.30 (0.23) −0.03 (−0.12 to 0.06) 0.56 2.28 (0.22) −0.01 (−0.05 to 0.03) 0.50 2.30 (0.21) −0.02 (−0.05 to 0.01) 0.29
Group A (Calcium and/or Aluminium binders).
Group B (Sevelamer hydrochloride alone).
Group C (Lanthanum carbonate alone).
Group D (Sevelamer hydrochloride and Calcium and/or Aluminium binders).
Group E (Lanthanum carbonate and Calcium and/or Aluminium binders).
#Observed mean level in mmol/L (standard deviation).
*Estimated mean difference in mmol/L (95% confidence interval) after adjusted for sex, age and diabetes.


















Figure 1 Pre-dialysis mean serum level of bicarbonate, phosphate, potassium and corrected calcium different combinations of
phosphate binders.
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Table 6 Pre-dialysis mean serum bicarbonate, phosphate, potassium and corrected calcium for separate doses of sevelamer hydrochloride
June 2009 December 2009 June 2010
Sevelamer hydrochloride Mean (SD)# Mean difference (95% CI)* P-trend Mean (SD)# Mean difference (95% CI)* P-trend Mean (SD)# Mean difference (95% CI)* P-trend
Bicarbonate
Non SH user* 22.83 (2.93) ref 22.77 (2.88) ref 22.85 (2.91) ref
Low dose 22.16 (2.53) −0.56 (−1.16 to 0.04) 22.21 (2.53) −0.16 (−0.63 to 0.32) 22.34 (2.56) −0.22 (−0.63 to 0.20)
Moderate dose 21.06 (2.68) −1.66 (−2.18 to −1.13) 21.31 (2.62) −0.99 (−1.39 to −0.59) 21.61 (2.62) −0.94 (−1.27 to −0.61)
High dose 20.66 (3.14) −1.89 (−2.51 to −1.26) <0.001 20.61 (3.30) −1.60 (−2.03 to −1.16) <0.001 21.04 (3.31) −1.27 (−1.63 to −0.91) <0.001
Phosphate^
Non SH user* 1.55 (0.52) ref 1.57 (0.54) ref 1.57 (0.55) ref
Low dose 1.44 (0.43) −0.07 (−0.17 to 0.03) 1.44 (0.40) −0.09 (−0.17 to −0.01) 1.43 (0.42) −0.06 (−0.13 to 0.01)
Moderate dose 1.50 (0.44) 0.03 (−0.06 to 0.12) 1.51 (0.45) −0.01 (−0.08 to 0.06) 1.49 (0.46) −0.05 (−0.10 to 0.01)
High dose 1.89 (0.54) 0.14 (0.03 to 0.26) 0.03 1.86 (0.53) 0.08 (0.01 to 0.16) 0.07 1.84 (0.53) 0.04 (−0.02 to 0.10) 0.53
Potassium
Non SH user* 4.85 (0.70) ref 4.83 (0.70) ref 4.85 (0.72) ref
Low dose 4.99 (0.68) 0.07 (−0.07 to 0.22) 4.97 (0.67) 0.09 (−0.03 to 0.20) 4.99 (0.65) 0.07 (−0.03 to 0.17)
Moderate dose 5.14 (0.72) 0.20 (0.07 to 0.33) 5.07 (0.70) 0.16 (0.07 to 0.26) 5.09 (0.69) 0.15 (0.07 to 0.23)
High dose 5.19 (0.72) 0.21 (0.05 to 0.37) <0.001 5.16 (0.72) 0.21 (0.11 to 0.32) <0.001 5.14 (0.70) 0.17 (0.09 to 0.26) <0.001
Corrected Calcium^
Non SH user* 2.34 (0.19) ref 2.35 (0.19) ref 2.36 (0.19) ref
Low dose 2.35 (0.18) −0.04 (−0.08 to 0.00) 2.35 (0.18) −0.03 (−0.06 to 0.00) 2.35 (0.18) −0.04 (−0.06 to −0.01)
Moderate dose 2.32 (0.20) −0.03 (−0.07 to 0.00) 2.33 (0.19) −0.03 (−0.06 to −0.01) 2.35 (0.18) −0.04 (−0.06 to −0.02)
High dose 2.27 (0.19) −0.05 (−0.10 to −0.01) 0.02 2.28 (0.18) −0.05 (−0.08 to −0.02) <0.001 2.29 (0.18) −0.04 (−0.07 to −0.02) <0.001
SH Low Dose (SH <2.5 g/day) – 1 to 3 tabs per day.
SH Medium Dose (SH 2.5-4.8 g/day) – 4 to 6 tabs per day.
SH High Dose (SH >4.8 g/day) – 7 to 9 tabs per day.
#Observed mean level in mmol/L (standard deviation).
*Estimated mean difference in mmol/L (95% confidence interval) after adjusted for sex, age and diabetes.


















Figure 2 Pre-dialysis mean serum bicarbonate, phosphate, potassium and corrected calcium for separate doses of sevelamer
hydrochloride.
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through dialysis does not result in thirst increase, fluid
overload, or significant interdialytic weight gain variation,
which are common undesirable effects observed during
the oral administration of alkali salts. Sonikian et al. study
[13] established that sevelamer-induced acidosis could be
successfully managed on the long-term by increasing
dialysate bicarbonate concentration. Sevelamer carbonate
(SC) is as good as sevelamer hydrochloride (SH) in terms
of hyperphosphatemia control with a better outcome in
serum bicarbonate balance [25]. However, SC is not avail-
able in Australia. Alternatively, switching from SH to lan-
thanum carbonate (LC) may improve metabolic acidosis
and hyeprkalemia [26-28]. In our units (both Melbourne
Health & Western Health), it was a standard practice to
supplement bicarbonate at monthly blood audit when
serum bicarbonate fell below 18. Given the results, the use
of these supplements either bicarbonate bath 40 or oral
supplements would only bias toward a negative effect in
the study for subjects taking sevelamer hydrochloride.
There are no data on the most appropriate method for
achieving the target bicarbonate. Complete correction of
pre-dialysis metabolic acidosis in haemodialysis patients
may lead to post-dialysis metabolic alkalosis and conse-
quently hypoventilation, phosphate transfer into cells and
a higher risk of soft tissue and vascular calcification.
Therefore, further studies are needed to identify the most
appropriate target of serum bicarbonate in Haemodialysis
patients and the most appropriate method for achieving
the target bicarbonate.
Conclusion
There is a tendency in practice to combine phosphate
binders in an attempt to improve efficacy or to minimize
side effects of binders. Phosphate binders’ constituents
have alkalotic or acidotic properties and may contribute
to/protect against a predisposition to metabolic acidosis
pre-dialysis. This may be dose dependant in patients
taking SH. Clinical implications of phosphate binders re-
lated metabolic acidosis need to be determined in pro-
spective studies.
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